P230001/S014: ColoSense
FDA’s recorded scope: ColoSense Sample preservative shelf-life extension from the original PMA approval of 12 months to 18 months in this current supplement S014.
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 6 FDA records to the applicant name Geneoscopy, Inc.. It includes 1 original PMA approval. 3 entries are PMA supplements. 2 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from May 3, 2024 to Sep 8, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code SBB appears in 6 of the 6 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P230001, with 6 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 2220 Welsch Industrial Ct., St. Louis, MO, 63146. Recorded on P230001/S014, decision dated Sep 8, 2026.
System, Colorectal Neoplasia, Rna Markers And Hemoglobin Detection.
FDA’s recorded scope: ColoSense Sample preservative shelf-life extension from the original PMA approval of 12 months to 18 months in this current supplement S014.
FDA’s recorded scope: ColoSense is intended for the qualitative detection of colorectal neoplasia associated RNA markers and for the presence of occult hemoglobin in human stool. ColoSense is a single-site test performed at Geneoscopy, Inc. A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA), or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults, 45 years of age or older, who are at typical average-risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.
FDA’s recorded scope: approval for modifying the concentration of a reagent used in the manufacturing process of QC materials and the qualification of an alternate reagent supplier
FDA’s recorded scope: Submission is approved.
FDA’s recorded scope: approval to modify the volume of specific kit reagents during the manufacturing process
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
MedtechLedger links 1 FDA enforcement entry through the recorded recalling firm or an exact submission number published in FDA’s recall data. 1 Class II records are represented. Each row is an enforcement entry; one recall event can cover several product entries. These counts describe this collection and do not measure a manufacturer’s safety record or an injury rate.
| Recall / product | Company | Classification | Report date | Source |
|---|---|---|---|---|
| Geneoscopy, Inc. | Class II | Jul 9, 2025 | FDA |
Connections use the recorded recalling firm or the submission identifiers shown below. A shared submission connects the records; it does not establish that differently named legal applicants are interchangeable. Use the exact affected models, lots and instructions on each notice.
Source updated Nov 11, 2026. Retrieved Nov 20, 2026.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ColoSenseP230001/S014 | Geneoscopy, Inc. | PMA supplement | Sep 8, 2026 | FDA |
ColoSenseP230001/S012 | Geneoscopy, Inc. | PMA supplement | Aug 27, 2026 | FDA |
ColoSenseP230001/S011 | Geneoscopy, Inc. | PMA supplement | Oct 24, 2025 | FDA |
ColoSenseP230001/S009 | Geneoscopy, Inc. | PMA supplement | Sep 15, 2025 | FDA |
ColoSenseP230001/S010 | Geneoscopy, Inc. | PMA supplement | Aug 14, 2025 | FDA |
ColoSenseP230001 | Geneoscopy, Inc. | PMA approval | May 3, 2024 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 20, 2026.